KCTD11 (KCASH1): A Comprehensive Review of Structure, Function, and Role in Disease

Introduction and Summary

KCTD11, also known as REN (retinoic acid-, EGF-, and NGF-induced gene) or KCASH1 (KCTD Containing-Cullin3 Adaptor, Suppressor of Hedgehog), is a BTB/POZ domain-containing protein that functions as a substrate-specific adapter for the Cullin3-RING E3 ubiquitin ligase complex (CRL3). The gene maps to human chromosome 17p13.2 and encodes a protein of approximately 232 amino acids (26 kDa) that plays critical roles in neural development, cell cycle regulation, and tumor suppression [dimarcotullio-2004-hedgehog-suppressor-abstract].

The primary molecular function of KCTD11 is to serve as a substrate receptor that recruits specific proteins for ubiquitination and subsequent proteasomal degradation. Its best-characterized substrate is histone deacetylase 1 (HDAC1), whose degradation by CRL3-KCTD11 leads to hyperacetylation and inactivation of the Gli transcription factors, thereby suppressing Hedgehog signaling [canettieri-2010-gli-acetylation-abstract]. More recently, SALL4, a stemness regulator, has been identified as another CRL3-KCTD11 substrate [severini-2023-sall4-substrate-abstract]. Through these mechanisms, KCTD11 acts as a potent tumor suppressor whose expression is frequently reduced or lost in multiple cancer types, most notably medulloblastoma, prostate adenocarcinoma, hepatocellular carcinoma, and lung cancer.

Discovery and Evolutionary Context

The gene encoding KCTD11 was originally identified in mouse as "REN," a developmentally regulated gene that promotes neural cell differentiation. Gallo and colleagues (2002) discovered that mouse Ren expression was upregulated by neurogenic signals including retinoic acid, epidermal growth factor (EGF), and nerve growth factor (NGF) in pluripotent embryonic stem cells and neural progenitor cell lines [gallo-2002-neural-differentiation-abstract]. The mouse protein consists of 232 amino acids with an N-terminal BTB/POZ domain and multiple predicted sites for post-translational modifications including myristoylation and phosphorylation. Northern blot analysis demonstrated peak expression at embryonic day 8.5, with localization in neural tissues including the neural tube and dorsal root ganglia [gallo-2002-neural-differentiation-abstract].

The human ortholog was subsequently cloned and characterized by Di Marcotullio and colleagues (2004), who demonstrated 91% amino acid identity with the mouse protein [dimarcotullio-2004-hedgehog-suppressor-abstract]. The human gene is intronless and maps to chromosome 17p13.2, a region frequently subject to loss of heterozygosity (LOH) in various cancers. The gene was named KCTD11 based on sequence similarity to the tetramerization domain of voltage-gated potassium channels, though KCTD11 does not function as a potassium channel. The KCASH1 designation was later adopted to reflect its function as a Cullin3 adaptor and suppressor of Hedgehog signaling [desmaele-2011-kcash-family-abstract].

KCTD11 belongs to a larger family of 26 KCTD proteins in humans. Phylogenetic analysis groups KCTD11 in the E-group along with KCTD21 (KCASH2) and KCTD6 (KCASH3), which share functional similarity as Hedgehog pathway suppressors [liu-2013-kctd-family-review-abstract]. These three proteins comprise the KCASH family, capable of forming homo- and hetero-oligomeric complexes that function coordinately to regulate HDAC1 degradation and Hedgehog signaling [desmaele-2011-kcash-family-abstract].

Protein Structure and Molecular Organization

KCTD11 contains a conserved N-terminal BTB/POZ (Bric-a-brac, Tramtrack, Broad-complex/Poxvirus and Zinc finger) domain spanning approximately 95 amino acids. The core BTB fold comprises five alpha-helices organized into two sets of hairpins, capped at one end by three beta-strands [pinkas-2017-kctd-structural-abstract]. This domain mediates protein oligomerization and interaction with Cullin3. The C-terminal region of KCTD11 contains the KCTD11/21_C domain (Pfam: PF19329), which is involved in substrate recognition.

Two protein isoforms exist: a shorter form (sKCTD11, 232 amino acids) and a longer variant (lKCTD11) with an extended N-terminus of approximately 39 additional residues [liu-2013-kctd-family-review-abstract]. Only the lKCTD11 form has a complete BTB domain, yet remarkably, even the shorter variant retains Cullin3-binding activity [liu-2013-kctd-family-review-abstract].

The oligomeric state of KCTD11 has been the subject of investigation. Initial biophysical characterization using gel filtration and light scattering suggested that KCTD11 forms stable tetramers, in contrast to the pentameric assemblies observed for the related protein KCTD5 [correale-2011-kctd11-organization-abstract]. Homology-based modeling suggested a 4:4 stoichiometry for the KCTD11-Cullin3 complex [correale-2011-kctd11-organization-abstract]. However, subsequent electron microscopy studies revealed that the BTB domain can also adopt pentameric states, suggesting structural flexibility [angrisani-2021-kctd-cancer-review-abstract]. The binding interface with Cullin3 involves aromatic residues, particularly Phe102 and Tyr103, in the POZ/BTB domain [correale-2011-kctd11-organization-abstract].

Despite differences in oligomeric state, tetrameric KCTD11 and pentameric KCTD5 share a similar cavity at the subunit-subunit interface for Cullin3 binding [correale-2011-kctd11-organization-abstract]. This structural conservation enables both proteins to function as Cullin3 adaptors, though they recognize different substrates.

More recently, AlphaFold v2.0 has been used to predict the full-length pentameric structure of KCTD11 [esposito-2022-alphafold-kctd-abstract]. These predictions classify KCTD11 within Cluster 2, sub-Cluster 2B alongside KCTD21 based on structural similarities. The predicted pentamer forms a propeller-like assembly with a central cavity delimited by beta-strands. Molecular dynamics simulations spanning 200 nanoseconds validated the overall integrity of the pentameric BTB and CTD domains [esposito-2022-alphafold-kctd-abstract]. Structural comparison between AlphaFold-predicted KCTD11 and KCTD21 yielded an RMSD of 2.36 Angstroms with 579 Calpha atoms aligned, demonstrating substantial structural conservation despite sequence divergence (31.6% identity in CTD domains) [esposito-2022-alphafold-kctd-abstract].

Primary Molecular Function: E3 Ubiquitin Ligase Adaptor Activity

The principal molecular function of KCTD11 is to act as a substrate-specific adapter for the BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex. In this capacity, KCTD11 bridges the Cullin3 scaffold protein to specific substrates, targeting them for polyubiquitination and subsequent proteasomal degradation [canettieri-2010-gli-acetylation-abstract].

HDAC1 as a Substrate

The best-characterized substrate of CRL3-KCTD11 is histone deacetylase 1 (HDAC1). The landmark study by Canettieri and colleagues (2010) in Nature Cell Biology established that KCTD11, in complex with Cullin3, promotes the ubiquitination and degradation of HDAC1 [canettieri-2010-gli-acetylation-abstract]. This discovery was crucial for understanding how KCTD11 regulates Hedgehog signaling.

Both KCASH1 (KCTD11) and KCASH2 (KCTD21) can directly bind HDAC1, while KCASH3 (KCTD6) requires heterodimerization with KCASH1 to effectively target HDAC1 [desmaele-2011-kcash-family-abstract]. This hetero-oligomerization enables coordinate regulation of HDAC1 levels by the KCASH family.

SALL4 as a Substrate

More recently, the stemness regulator SALL4 (Spalt-like transcriptional factor 4) was identified as another CRL3-KCTD11 substrate through proteomic analysis [severini-2023-sall4-substrate-abstract]. SALL4 interacts with KCTD11 through its zinc finger cluster 1 (ZFC1) domain. CRL3-KCTD11 induces polyubiquitylation and degradation of wild-type SALL4, but not a SALL4 mutant lacking the ZFC1 domain [severini-2023-sall4-substrate-abstract]. The identification of SALL4 as a substrate reveals additional mechanisms by which KCTD11 suppresses tumorigenesis.

Protein Interaction Partners

According to the BioGRID database, KCTD11 has multiple confirmed interaction partners beyond its substrates. The key interactions include: (1) CUL3 (Cullin3), which forms the scaffold of the CRL3 complex via direct binding to the KCTD11 BTB domain; (2) KCTD6 (KCASH3) and KCTD21 (KCASH2), with which KCTD11 can form heteropentameric assemblies [desmaele-2011-kcash-family-abstract]; (3) CTNNB1 (beta-catenin), which binds directly to the BTB domain of KCTD11 [yang-2021-lung-cancer-wnt-hippo-abstract]; and (4) RBX1, the RING-box protein that completes the BCR E3 ligase complex. These interactions reflect the dual role of KCTD11 as both an E3 ligase adaptor and a direct regulator of signaling pathways.

Signaling Pathway Regulation

Hedgehog Pathway Suppression

The Hedgehog (Hh) signaling pathway is crucial for embryonic development and is frequently dysregulated in cancer, particularly medulloblastoma. The transcriptional output of Hedgehog signaling is mediated by the Gli family of transcription factors (Gli1, Gli2, Gli3). KCTD11 functions as a negative regulator of this pathway through multiple mechanisms.

The primary mechanism involves HDAC1 degradation and subsequent Gli acetylation. Gli1 and Gli2 are acetylated proteins, and their HDAC-mediated deacetylation promotes transcriptional activation [canettieri-2010-gli-acetylation-abstract]. Acetylation of Gli1 and Gli2, catalyzed by the histone acetyltransferase p300, inhibits their transcriptional activity by preventing recruitment to target promoters. HDAC1 and HDAC2 remove these acetyl groups, restoring Gli activity. Hedgehog signaling induces HDAC1 expression, creating a positive feedback loop that amplifies pathway activity [canettieri-2010-gli-acetylation-abstract].

CRL3-KCTD11 turns off this mechanism by degrading HDAC1, thereby preserving Gli acetylation and blocking transcriptional activity. Loss of KCTD11, as occurs in medulloblastoma, allows HDAC1 accumulation and consequent Gli1 deacetylation and activation [canettieri-2010-gli-acetylation-abstract].

Additionally, the original study by Di Marcotullio et al. (2004) demonstrated that KCTD11/REN retains Gli1 in the cytoplasm under conditions that would otherwise trigger its nuclear translocation [dimarcotullio-2004-hedgehog-suppressor-abstract]. This cytoplasmic retention prevents Gli1 from accessing nuclear target genes.

The SALL4 pathway adds another layer of Hedgehog regulation. SALL4, HDAC1, and GLI1 form a trimeric complex that promotes GLI1 deacetylation, enhancing pathway activation [severini-2023-sall4-substrate-abstract]. By degrading both HDAC1 and SALL4, CRL3-KCTD11 disrupts this oncogenic complex.

Wnt/Beta-Catenin Pathway Regulation

Beyond Hedgehog signaling, KCTD11 has been shown to regulate the Wnt/beta-catenin pathway. In non-small cell lung cancer, Yang and colleagues (2021) demonstrated that KCTD11 binds to beta-catenin through its BTB domain [yang-2021-lung-cancer-wnt-hippo-abstract]. This interaction promotes beta-catenin phosphorylation and inhibits its nuclear translocation, thereby suppressing Wnt pathway transcriptional activity. Deletion of the BTB domain eliminated both beta-catenin binding and tumor-suppressive effects [yang-2021-lung-cancer-wnt-hippo-abstract].

Hippo Pathway Activation

KCTD11 also regulates the Hippo signaling pathway, which controls organ size and has tumor-suppressive functions. Studies in hepatocellular carcinoma [tong-2017-hcc-hippo-abstract] and lung cancer [yang-2021-lung-cancer-wnt-hippo-abstract] demonstrated that KCTD11 promotes phosphorylation of YAP at Ser127, leading to YAP cytoplasmic retention and inactivation. This prevents YAP-driven transcription of proliferative and anti-apoptotic genes.

Interestingly, KCTD11 lost its stimulatory effect on the Hippo pathway upon beta-catenin knockdown, establishing beta-catenin as essential for Hippo pathway regulation by KCTD11 [yang-2021-lung-cancer-wnt-hippo-abstract]. This reveals crosstalk between the Wnt and Hippo pathways mediated by KCTD11.

The hepatocellular carcinoma study identified three distinct mechanisms by which KCTD11 activates p21, a key cell cycle inhibitor: (1) YAP inactivation, (2) p53 stabilization via LATS2, and (3) promotion of the MST1/GSK3beta/p21 signaling axis [tong-2017-hcc-hippo-abstract]. These mechanisms function independently of p53 status.

Subcellular Localization and Tissue Expression

KCTD11 exhibits both cytoplasmic and nuclear localization, with the distribution varying between normal and tumor tissues. According to immunohistochemical studies, normal tissues show predominantly nuclear KCTD11 staining (40-78% positive), while matching tumor samples show dramatically reduced nuclear staining (0-18%) [mancarelli-2010-sp1-methylation-abstract]. This suggests that nuclear localization may be important for KCTD11's tumor-suppressive function.

Functionally, KCTD11 operates primarily in the cytoplasm where it can sequester Gli1 and prevent its nuclear translocation [dimarcotullio-2004-hedgehog-suppressor-abstract]. The protein also influences the nuclear-cytoplasmic shuttling of other signaling molecules, including beta-catenin and YAP [yang-2021-lung-cancer-wnt-hippo-abstract][tong-2017-hcc-hippo-abstract].

Regarding tissue distribution, KCTD11 is broadly expressed across human tissues according to the Human Protein Atlas, with particularly notable expression in the cerebellum and nervous system tissues. In adult cerebellum, KCTD11 shows higher expression compared to whole brain, while medulloblastoma samples show significantly reduced expression. Real-time PCR analysis demonstrated reduced KCTD11 expression relative to normal adult cerebellum in 70% (14 of 20) of medulloblastoma samples examined [dimarcotullio-2004-hedgehog-suppressor-abstract]. Interestingly, neural stem cells show even lower KCTD11 levels than medulloblastoma, consistent with the role of KCTD11 as a marker and regulator of neuronal differentiation [gallo-2002-neural-differentiation-abstract].

Role in Development

KCTD11 plays important roles in neural development. The original discovery of the gene revealed its induction by neurogenic signals (retinoic acid, EGF, NGF) and its ability to promote neuronal differentiation while inducing growth arrest [gallo-2002-neural-differentiation-abstract]. Overexpression of REN/KCTD11 induced neuronal differentiation and p27(KIP1) expression in neural progenitor cell lines, while inhibition impaired the induction of proneural genes neurogenin-1 and NeuroD [gallo-2002-neural-differentiation-abstract].

In cerebellar development, KCTD11 is expressed in differentiating rather than proliferating granule cell progenitors (GCPs). The Hedgehog pathway normally drives GCP proliferation, and KCTD11 antagonizes this by suppressing Hedgehog signaling, thereby promoting the transition from proliferation to differentiation [dimarcotullio-2004-hedgehog-suppressor-abstract]. Loss of KCTD11 disrupts this developmental checkpoint, contributing to medulloblastoma formation.

Role in Cancer and Tumor Suppression

KCTD11 functions as a tumor suppressor gene, and its expression is reduced or lost in multiple cancer types.

Medulloblastoma

Medulloblastoma, the most common malignant childhood brain tumor, is the cancer type most strongly associated with KCTD11 loss. Approximately 30% of medulloblastomas belong to the Sonic Hedgehog (SHH) molecular subgroup, characterized by constitutive pathway activation. Loss of heterozygosity on chromosome 17p13 occurs in up to 50% of medulloblastomas, and KCTD11 at 17p13.2 is a key gene affected by this deletion [dimarcotullio-2004-hedgehog-suppressor-abstract].

Studies have shown that KCTD11 deletion occurs in approximately 35-39% of primary medulloblastoma samples, with hemizygous tumors displaying 5-fold lower mRNA levels compared to normal cerebellum [dimarcotullio-2004-hedgehog-suppressor-abstract]. All three KCASH family members show reduced expression in medulloblastoma compared to normal cerebellum [desmaele-2011-kcash-family-abstract].

Prostate Cancer

KCTD11 loss of heterozygosity is a common genetic lesion in human prostate adenocarcinoma. Nuclear KCTD11 protein expression is strongly reduced in primary prostate cancer, correlating with overexpression of Hedgehog pathway proteins [angrisani-2021-kctd-cancer-review-abstract].

Hepatocellular Carcinoma

KCTD11 is lower expressed in hepatocellular carcinoma tumor tissues than peritumoral tissues, and patients with low KCTD11 expression show shorter survival rates [tong-2017-hcc-hippo-abstract]. The protein suppresses HCC growth through Hippo pathway activation and inhibits metastasis through suppression of MMPs and EMT [tong-2017-hcc-hippo-abstract].

Lung Cancer

KCTD11 is under-expressed in lung cancer tissues and negatively correlates with tumor differentiation, TNM stage, and lymph node metastasis [yang-2021-lung-cancer-wnt-hippo-abstract]. Kaplan-Meier analysis demonstrates that KCTD11-positive patients have significantly better survival outcomes.

Other Cancers

Reduced KCTD11 expression has been documented in cancers of the larynx, esophagus, stomach, colon-rectum, urinary bladder, breast, gallbladder, endometrium, and ovary [angrisani-2021-kctd-cancer-review-abstract][mancarelli-2010-sp1-methylation-abstract].

Role in Peripheral Neuropathy: Charcot-Marie-Tooth Disease

A recent breakthrough discovery (2025) has identified KCTD11 as a novel gene responsible for autosomal recessive intermediate Charcot-Marie-Tooth disease (RI-CMTE), expanding the disease associations of KCTD11 beyond cancer [gadacha-2025-cmt-neuropathy-abstract]. Genetic studies in ten patients from five unrelated families identified five distinct bi-allelic loss-of-function KCTD11 variants. The patients present with middle-to-late onset (typically ages 25-40) slowly progressive neuropathy characterized by distal motor weakness, foot deformities, hand weakness, and intermediate nerve conduction velocities (25-45 m/s at the median nerve) [gadacha-2025-cmt-neuropathy-abstract].

Mechanistic studies revealed that KCTD11 plays a critical role in peripheral nerve myelination and maintenance. In Kctd11-/- mice, progressive myelin abnormalities including abnormal myelin infoldings and increased g-ratio (indicating thinner myelin) develop with age, most pronounced in distal nerves [gadacha-2025-cmt-neuropathy-abstract]. In vitro studies using dorsal root ganglion neuron/Schwann cell co-cultures demonstrated that KCTD11 ablation impairs myelination. The pathogenic mechanism involves dysregulation of the same signaling pathways controlled by KCTD11 in cancer contexts: HDAC1, Wnt/beta-catenin (increased beta-catenin indicating pathway activation), Sonic Hedgehog (upregulation of Gli2), and Hippo/YAP (increased CTGF/CCN2 indicating pathway inhibition) [gadacha-2025-cmt-neuropathy-abstract]. These findings demonstrate that KCTD11 functions as a key regulator of peripheral nerve physiology, particularly in myelin maintenance through coordinated regulation of these signaling pathways in Schwann cells.

Gene Regulation and Epigenetic Silencing

KCTD11 expression is regulated by both transcriptional and epigenetic mechanisms. The gene promoter contains a CpG island of 623 bp spanning 72 CpG dinucleotides, and six putative binding sites for the Sp1 transcription factor [mancarelli-2010-sp1-methylation-abstract].

Sp1 strongly activates the TATA-less KCTD11 promoter, particularly through binding sites (Sp1-E and Sp1-F) positioned near the transcription start site [mancarelli-2010-sp1-methylation-abstract]. Treatment with the demethylating agent 5'-aza-2'-deoxycytidine significantly increased KCTD11 mRNA levels in colon cancer cell lines, demonstrating that promoter hypermethylation contributes to gene silencing in cancer [mancarelli-2010-sp1-methylation-abstract].

The balance between DNA methylation and Sp1 binding may represent a mechanism regulating tissue-specific KCTD11 expression. In cancer, promoter hypermethylation shifts this balance toward gene silencing, contributing to tumor suppressor inactivation.

Therapeutic Implications

The role of KCTD11 in suppressing Hedgehog signaling has therapeutic implications. KCASH proteins represent a potential class of endogenous agents through which Hedgehog pathway-addicted tumors might be targeted [desmaele-2011-kcash-family-abstract]. Strategies to reactivate or increase KCASH1/KCTD11 expression could suppress Hedgehog signaling in tumors.

The identification of SALL4 as a CRL3-KCTD11 substrate provides another therapeutic avenue. Inhibition of SALL4 suppresses SHH medulloblastoma growth in both murine and patient-derived xenograft models [severini-2023-sall4-substrate-abstract]. Thalidomide treatment, which redirects SALL4 to CRL4-CRBN-mediated degradation, impaired PDX cell proliferation [severini-2023-sall4-substrate-abstract].

Given the epigenetic silencing of KCTD11 in many cancers, demethylating agents represent another potential therapeutic approach to restore KCTD11 expression and tumor-suppressive function.

Open Questions

Several important questions remain regarding KCTD11 biology:

1. Complete substrate repertoire: While HDAC1 and SALL4 are established substrates, the full range of proteins targeted by CRL3-KCTD11 for degradation remains unknown. Systematic proteomics approaches may identify additional substrates relevant to development and cancer.

2. Tissue-specific functions: KCTD11 is expressed in multiple tissues, but its functions outside the nervous system are less well characterized. Understanding tissue-specific roles could reveal new therapeutic opportunities.

3. Oligomeric state regulation: The apparent flexibility between tetrameric and pentameric states raises questions about whether oligomeric state is dynamically regulated and functionally significant.

4. KCASH family coordination: The three KCASH proteins can form hetero-oligomers, but the precise circumstances under which homo- versus hetero-oligomers form, and their differential substrate specificities, require further investigation.

5. Post-translational modifications: The KCTD11 protein contains predicted sites for myristoylation and phosphorylation, but the functional significance of these modifications is unexplored.

6. Relationship to potassium channels: Despite sequence similarity to potassium channel tetramerization domains, KCTD11 does not appear to function in potassium conductance. The evolutionary relationship and any functional connection to ion channels remains unclear.

7. Therapeutic development: Whether KCTD11 expression can be therapeutically restored in tumors with epigenetic silencing, or whether its downstream effects can be mimicked pharmacologically, remains to be determined.

8. Structural details of substrate recognition: High-resolution structures of KCTD11 in complex with its substrates (HDAC1, SALL4) would provide insights into the molecular basis of substrate recognition and potential strategies for therapeutic intervention.

9. Peripheral nervous system function: The recent discovery that KCTD11 mutations cause Charcot-Marie-Tooth disease reveals a previously unappreciated role in peripheral nerve myelination and Schwann cell function. The precise mechanisms by which KCTD11 regulates myelin maintenance, and whether this involves the same substrate repertoire as in the CNS and cancer contexts, require further investigation.

References

1. gallo-2002-neural-differentiation: Gallo R, Zazzeroni F, Alesse E, et al. REN: a novel, developmentally regulated gene that promotes neural cell differentiation. J Cell Biol. 2002;158(4):731-740. PMID: 12186855. DOI: 10.1083/jcb.200206024

2. dimarcotullio-2004-hedgehog-suppressor: Di Marcotullio L, Ferretti E, De Smaele E, et al. REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Proc Natl Acad Sci USA. 2004;101(29):10833-10838. PMID: 15249678. DOI: 10.1073/pnas.0400690101. PMC: PMC490020. URL: https://www.pnas.org/doi/10.1073/pnas.0400690101

3. canettieri-2010-gli-acetylation: Canettieri G, Di Marcotullio L, Greco A, et al. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol. 2010;12(2):132-142. PMID: 20081843. DOI: 10.1038/ncb2013. URL: https://www.nature.com/articles/ncb2013

4. mancarelli-2010-sp1-methylation: Mancarelli MM, Zazzeroni F, Ciccocioppo L, et al. The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors. Mol Cancer. 2010;9:172. PMID: 20591193. DOI: 10.1186/1476-4598-9-172. PMC: PMC2913982. URL: https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172

5. desmaele-2011-kcash-family: De Smaele E, Di Marcotullio L, Moretti M, et al. Identification and Characterization of KCASH2 and KCASH3, 2 Novel Cullin3 Adaptors Suppressing Histone Deacetylase and Hedgehog Activity in Medulloblastoma. Neoplasia. 2011;13(4):374-385. PMID: 21472142. DOI: 10.1593/neo.101630. PMC: PMC3071086. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3071086/

6. correale-2011-kctd11-organization: Correale S, Pirone L, Di Marcotullio L, et al. Molecular organization of the cullin E3 ligase adaptor KCTD11. Biochimie. 2011;93(4):715-724. PMID: 21237243. DOI: 10.1016/j.biochi.2010.12.014

7. liu-2013-kctd-family-review: Liu Z, Xiang Y, Sun G. The KCTD family of proteins: structure, function, disease relevance. Cell Biosci. 2013;3(1):45. PMID: 24268103. DOI: 10.1186/2045-3701-3-45. PMC: PMC3882106. URL: https://cellandbioscience.biomedcentral.com/articles/10.1186/2045-3701-3-45

8. tong-2017-hcc-hippo: Tong R, Yang B, Xiao H, et al. KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling. Oncotarget. 2017;8(23):37717-37729. DOI: 10.18632/oncotarget.17145. URL: https://www.oncotarget.com/article/17145/text/

9. pinkas-2017-kctd-structural: Pinkas DM, Sanvitale CE, Bufton JC, et al. Structural complexity in the KCTD family of Cullin3-dependent E3 ubiquitin ligases. Biochem J. 2017;474(22):3747-3761. PMID: 28963344. DOI: 10.1042/BCJ20170527. PMC: PMC5664961. URL: https://portlandpress.com/biochemj/article/474/22/3747/49544/

10. angrisani-2021-kctd-cancer-review: Angrisani A, Di Fiore A, De Smaele E, Moretti M. The emerging role of the KCTD proteins in cancer. Cell Commun Signal. 2021;19:56. PMID: 34001146. DOI: 10.1186/s12964-021-00737-8. PMC: PMC8127222. URL: https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8

11. yang-2021-lung-cancer-wnt-hippo: Yang M, Han Y, Han Q, et al. KCTD11 inhibits progression of lung cancer by binding to beta-catenin to regulate the activity of the Wnt and Hippo pathways. J Cell Mol Med. 2021;25(19):9411-9426. PMID: 34453479. DOI: 10.1111/jcmm.16883. PMC: PMC8500973. URL: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.16883

12. severini-2023-sall4-substrate: Lospinoso Severini L, Loricchio E, Navacci S, et al. SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma. Cell Death Differ. 2024;31(2):170-187. PMID: 38062245. DOI: 10.1038/s41418-023-01246-6. PMC: PMC10850099. URL: https://www.nature.com/articles/s41418-023-01246-6

13. esposito-2022-alphafold-kctd: Esposito L, Balasco N, Vitagliano L. AlphaFold Predictions Provide Insights into the Structural Features of the Functional Oligomers of All Members of the KCTD Family. Int J Mol Sci. 2022;23(21):13346. PMID: 36362127. DOI: 10.3390/ijms232113346. PMC: PMC9658877. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9658877/

14. gadacha-2025-cmt-neuropathy: Gadacha W, et al. Bi-allelic mutations in KCTD11 cause a new form of autosomal recessive intermediate Charcot-Marie-Tooth disease. bioRxiv (preprint). 2025. DOI: 10.1101/2025.06.30.661538. URL: https://www.biorxiv.org/content/10.1101/2025.06.30.661538v1

Citations

1. angrisani-2021-kctd-cancer-review-abstract.md
2. canettieri-2010-gli-acetylation-abstract.md
3. correale-2011-kctd11-organization-abstract.md
4. desmaele-2011-kcash-family-abstract.md
5. dimarcotullio-2004-hedgehog-suppressor-abstract.md
6. esposito-2022-alphafold-kctd-abstract.md
7. gadacha-2025-cmt-neuropathy-abstract.md
8. gallo-2002-neural-differentiation-abstract.md
9. liu-2013-kctd-family-review-abstract.md
10. mancarelli-2010-sp1-methylation-abstract.md
11. pinkas-2017-kctd-structural-abstract.md
12. severini-2023-sall4-substrate-abstract.md
13. tong-2017-hcc-hippo-abstract.md
14. yang-2021-lung-cancer-wnt-hippo-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan status: All objectives completed. Proceeding with the comprehensive, cited report.

Comprehensive research report: Human KCTD11 (KCASH1/REN; UniProt Q693B1)

Identity verification and gene/protein context
- Identity and aliases: KCTD11 is also known as KCASH1 (KCTD-containing Cullin3 adaptor, suppressor of Hedgehog 1) and REN; it encodes a 232-aa KCTD family protein. It is mapped to human chromosome 17p13.2 and is expressed in brain and cerebellum. These names and features are consistently used in foundational and review literature, aligning with UniProt Q693B1 and the BTB/POZ-containing annotation (Jul 2004; Nov 2021) (spiombi2019kctd15inhibitsthe pages 3-4, angrisani2021theemergingrole pages 6-7). URL/DOI: PNAS 2004 (https://doi.org/10.1073/pnas.0400690101); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).
- Domain architecture: KCTD11 contains an N‑terminal BTB/POZ domain (mediates oligomerization and Cul3 binding) and a divergent C‑terminal region often denoted KCTD11/21_C. Structural descriptions of KCASH/KCTD BTB assemblies support oligomeric (tetrameric/pentameric) adaptors that dock Cul3 (2025 review; 2019 KCTD15–KCASH2 BTB interaction) (navacci2025dissectingtherole pages 31-35, spiombi2019kctd15inhibitsthe pages 3-4). URL/DOI: J Cell Sci 2016 (contextual BTB/KCTD with USP21; https://doi.org/10.1242/jcs.188516); Oncogenesis 2019 (https://doi.org/10.1038/s41389-019-0175-6).
- Organism: Homo sapiens (Human). All cited studies referencing REN/KCTD11/KCASH1 in medulloblastoma and cancer are human or human cell models (Jul 2004; Jun 2010; Sep 2023) (spiombi2019kctd15inhibitsthe pages 3-4, angrisani2021theemergingrole pages 6-7, fiore2023kctd1isa pages 4-5).

1) Key concepts and definitions (current understanding)
- Molecular role: KCTD11/KCASH1 is a BTB/POZ-domain substrate adaptor for a CRL3 (Cullin 3–Rbx1) E3 ubiquitin ligase complex. Its principal identified substrate is HDAC1. By promoting HDAC1 ubiquitination and proteasomal degradation, KCASH1 increases GLI1 acetylation, thereby repressing GLI1-dependent transcription in the Hedgehog (Hh) pathway (Nov 2021 review; primary data summarized therein) (angrisani2021theemergingrole pages 6-7). URL/DOI: Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).
- Pathway definition: In vertebrate Hh signaling, SHH relieves PTCH inhibition of SMO, leading to GLI activation via primary cilia/centrosome trafficking and nuclear transactivation. KCASH proteins oppose this by degrading HDAC1 so that GLI1 remains acetylated/inactive and less nuclear (Nov 2021; background schema) (angrisani2021theemergingrole pages 7-9). URL/DOI: Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).
- Gene family context: KCASH1/KCTD11 is one member of the KCASH subfamily with KCASH2/KCTD21 and KCASH3/KCTD6. KCASH3 cannot recruit HDAC1 alone and functionally requires KCASH1 hetero-oligomerization to downregulate Hh, highlighting BTB-mediated combinatorial assemblies (Nov 2019; Nov 2021) (spiombi2019kctd15inhibitsthe pages 3-4, angrisani2021theemergingrole pages 6-7). URL/DOI: Oncogenesis 2019 (https://doi.org/10.1038/s41389-019-0175-6); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).

2) Recent developments and latest research (priority 2023–2024)
- 2023: KCTD1 modulates KCASH proteins. Di Fiore et al. showed KCTD1 stabilizes KCASH1 and KCASH2 by reducing their ubiquitination, increasing their half-lives, which secondarily increases HDAC1 ubiquitination/degradation and suppresses GLI1 transcriptional activity and proliferation in SHH‑dependent medulloblastoma lines (DAOY, D283) (Sep 2023) (fiore2023kctd1isa pages 2-3, fiore2023kctd1isa pages 4-5, fiore2023kctd1isa pages 5-8). URL/DOI: Neoplasia 2023 (https://doi.org/10.1016/j.neo.2023.100926).
- Family regulation theme: Prior KCTD15 work (2019) reported BTB–BTB interaction with KCASH2 that stabilizes KCASH2 and inhibits Hh signaling; the 2023 KCTD1 study generalizes and extends this inter-KCTD stabilization to include KCASH1, expanding potential regulatory nodes within the KCTD/KCASH network (Nov 2019; Sep 2023) (spiombi2019kctd15inhibitsthe pages 3-4, fiore2023kctd1isa pages 2-3). URL/DOIs: Oncogenesis 2019 (https://doi.org/10.1038/s41389-019-0175-6); Neoplasia 2023 (https://doi.org/10.1016/j.neo.2023.100926).
- Structural/assembly perspective: A recent synthesis depicts REN/KCTD11 BTB oligomers engaging Cul3 with models where a BTB tetramer can recruit multiple Cul3 molecules. This supports avidity/stoichiometry considerations in substrate ubiquitination, although high-resolution structures specific for KCTD11 remain to be fully resolved (2025 synthesis citing BTB–Cul3 assemblies) (navacci2025dissectingtherole pages 31-35). URL: not provided in excerpt (navacci2025dissectingtherole pages 31-35).

3) Current applications and real-world implementations
- Disease biomarker and tumor suppressor: KCTD11 deletion/downregulation in SHH‑medulloblastoma supports its use as a tumor suppressor marker; expression is widely reduced in multiple carcinomas (e.g., prostate, ovarian, gastrointestinal, lung, breast) per aggregated datasets and pathology surveys (Jun 2010; Nov 2021) (angrisani2021theemergingrole pages 6-7). URL/DOIs: Mol Cancer 2010 (https://doi.org/10.1186/1476-4598-9-172); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).
- Mechanism-informed targeting: Preclinical MB models demonstrate that enhancing KCASH1/2 stability (via KCTD1) reduces GLI1 targets and cell proliferation, suggesting potential strategies to stabilize KCASH adaptors or mimic their function to suppress SHH pathway activity (Sep 2023) (fiore2023kctd1isa pages 4-5, fiore2023kctd1isa pages 5-8). URL/DOI: Neoplasia 2023 (https://doi.org/10.1016/j.neo.2023.100926).
- Therapeutic concepts: Reviews propose reactivating KCASH1/2 (e.g., demethylating agents in cases of promoter methylation; or stabilizers such as KCTD1-like interventions), direct HDAC1 inhibition, and GLI antagonists for SHH-driven tumors. This leverages the KCASH–HDAC1–GLI axis (Oct 2023 review of E3/adaptors; Aug 2015 GLI-targeting overview; Nov 2021 KCASH review) (spiombi2019kctd15inhibitsthe pages 1-2, fiore2023kctd1isa pages 2-3, angrisani2021theemergingrole pages 6-7). URL/DOIs: Exp Mol Med 2023 (https://doi.org/10.1038/s12276-023-01087-w); Trends Pharmacol Sci 2015 (https://doi.org/10.1016/j.tips.2015.05.006); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).

4) Expert opinions and analysis from authoritative sources
- Foundational identification: REN/KCTD11 was identified as a Hedgehog antagonist deleted in human medulloblastoma, establishing its tumor suppressor function and pathway context (Jul 2004) (spiombi2019kctd15inhibitsthe pages 3-4). URL/DOI: PNAS 2004 (https://doi.org/10.1073/pnas.0400690101).
- Family-level consensus: The KCASH subfamily acts as negative regulators of GLI transcription by mediating HDAC1 degradation within CRL3 complexes; KCASH1 (KCTD11) is frequently downregulated in tumors and is considered a biomarker/therapeutic reactivation candidate (May 2021) (angrisani2021theemergingrole pages 6-7, angrisani2021theemergingrole pages 7-9). URL/DOI: Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).
- Cilium/centrosome hub: Regulation of GLI1 involves centrosomal/ciliary processes where KCTD6 and the DUB USP21 converge; although this focuses on KCTD6/GLI1, it frames how KCTD adaptors can influence GLI1 activation state and trafficking (Nov 2016) (spiombi2019kctd15inhibitsthe pages 3-4). URL/DOI: J Cell Sci 2016 (https://doi.org/10.1242/jcs.188516).

5) Relevant statistics and data
- Genomic loss: Allelic deletions encompassing 17p13.2–13.3 occur in up to approximately 50% of SHH‑medulloblastomas in some cohorts; REN/KCTD11 is among tumor suppressors in this interval (review synthesis; foundational work) (Nov 2021; Jul 2004) (angrisani2021theemergingrole pages 6-7, spiombi2019kctd15inhibitsthe pages 3-4). URL/DOIs: Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8); PNAS 2004 (https://doi.org/10.1073/pnas.0400690101).
- Expression downregulation across cancers: A 177-patient multi-cancer panel showed reduced KCTD11 protein levels are a widespread event, with regulatory involvement of Sp1 and promoter methylation (Jun 2010) (angrisani2021theemergingrole pages 6-7). URL/DOI: Mol Cancer 2010 (https://doi.org/10.1186/1476-4598-9-172).
- Functional half-lives and stabilization (2023): KCASH1 is short-lived (<2 h) and KCASH2 has a 6–12 h half-life; KCTD1 overexpression decreases KCASH1/2 ubiquitination, extends their half-lives comparably to MG132, increases HDAC1 ubiquitination, diminishes GLI1, and suppresses proliferation in SHH‑MB lines (Sep 2023) (fiore2023kctd1isa pages 4-5, fiore2023kctd1isa pages 5-8). URL/DOI: Neoplasia 2023 (https://doi.org/10.1016/j.neo.2023.100926).

Primary functional mechanism and localization
- Mechanism: KCTD11 assembles a CRL3-KCASH1 E3 ligase via its BTB/POZ domain to recruit HDAC1 for ubiquitination and proteasomal degradation. This shifts GLI1 toward the acetylated (inactive) state, impairing nuclear translocation and transcriptional activation of Hh targets (Nov 2021 synthesis; foundational/cited studies) (angrisani2021theemergingrole pages 6-7). URL/DOI: Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).
- Localization and cellular context: KCASH1/KCTD11 is enriched in brain/cerebellum; functional suppression of GLI1 activity occurs downstream of ciliary/centrosomal signal integration and manifests as reduced GLI1 nuclear transcription. The centrosome/primary cilium is a central GLI regulatory hub, with other KCTDs (e.g., KCTD6) and USP21 modulating GLI1 stability/activity at this locale, supporting a model where KCASH1’s control of HDAC1 intersects with ciliary GLI activation and nuclear entry (Nov 2016; review context; 2025 synthesis) (spiombi2019kctd15inhibitsthe pages 3-4, angrisani2021theemergingrole pages 7-9, navacci2025dissectingtherole pages 31-35). URL/DOIs: J Cell Sci 2016 (https://doi.org/10.1242/jcs.188516); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).

Interactions and complex assembly
- Partners: Cul3 and RBX1 (CRL3), HDAC1 (substrate), GLI1 (downstream readout), KCTD6/KCTD21 (KCASH3/2) via oligomerization, and regulatory interactions with KCTD15 and KCTD1 that stabilize KCASH proteins (Nov 2019; Sep 2023; Nov 2021) (spiombi2019kctd15inhibitsthe pages 3-4, fiore2023kctd1isa pages 2-3, angrisani2021theemergingrole pages 6-7). URL/DOIs: Oncogenesis 2019 (https://doi.org/10.1038/s41389-019-0175-6); Neoplasia 2023 (https://doi.org/10.1016/j.neo.2023.100926); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).
- Oligomerization/stoichiometry: BTB/POZ domains mediate homo- and hetero-oligomers among KCASH/KCTD proteins. Modeling suggests REN/KCTD11 oligomers can engage multiple Cul3 molecules (2025 synthesis), implying potential multivalent substrate presentation; KCASH3 requires KCASH1 to engage HDAC1 (Nov 2021; Nov 2019) (navacci2025dissectingtherole pages 31-35, angrisani2021theemergingrole pages 6-7, spiombi2019kctd15inhibitsthe pages 3-4). URL: not provided in excerpt (navacci2025dissectingtherole pages 31-35); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8); Oncogenesis 2019 (https://doi.org/10.1038/s41389-019-0175-6).

Disease relevance and genetics
- Medulloblastoma (SHH subgroup): REN/KCTD11 identified as a Hedgehog antagonist deleted in MB; reduction or loss of KCASH1 contributes to unchecked GLI activation and tumorigenesis in cerebellar granule neuron precursors (Jul 2004; Nov 2021) (spiombi2019kctd15inhibitsthe pages 3-4, angrisani2021theemergingrole pages 6-7). URL/DOIs: PNAS 2004 (https://doi.org/10.1073/pnas.0400690101); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).
- Broad cancer relevance: Downregulation of KCTD11 is common across multiple tumor types, with promoter methylation and Sp1 involvement in regulation documented (Jun 2010) (angrisani2021theemergingrole pages 6-7). URL/DOI: Mol Cancer 2010 (https://doi.org/10.1186/1476-4598-9-172).
- Constitutional microdeletions: 17p13 region microdeletions including KCTD11/REN occur in patients with neurodevelopmental phenotypes, emphasizing regional instability and potential tumor risk; this underscores KCTD11’s inclusion among tumor suppressors in the interval (Jul 2009 review of cases) (fiore2023kctd1isa pages 4-5). URL/DOI: Cytogenet Genome Res 2009 (https://doi.org/10.1159/000218743).

Therapeutic implications and directions
- Reactivation strategies: In tumors with epigenetic silencing of KCASH1/2, demethylating agents or interventions that increase transcription could restore KCASH function; Sp1/p53 balance and DNMT1-mediated promoter methylation have been implicated for KCASH2 and may analogously inform KCASH1 regulation (Apr 2021 KCASH2 promoter study; Nov 2021 review) (fiore2023kctd1isa pages 1-2, angrisani2021theemergingrole pages 6-7). URL/DOIs: Front Cell Dev Biol 2021 (https://doi.org/10.3389/fcell.2021.638508); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).
- Stabilization of KCASH adaptors: KCTD1 overexpression stabilizes KCASH1/2 and suppresses SHH signaling in MB cells; drug-like strategies that mimic this stabilizing effect could augment endogenous KCASH tumor suppressor activity (Sep 2023) (fiore2023kctd1isa pages 4-5, fiore2023kctd1isa pages 5-8). URL/DOI: Neoplasia 2023 (https://doi.org/10.1016/j.neo.2023.100926).
- Targeting the axis: Pharmacologic HDAC1 inhibition and direct GLI antagonists are orthogonal means to reduce GLI-driven transcription downstream of SMO, potentially overcoming SMO inhibitor resistance (Oct 2023 E3/adaptor review; Aug 2015 GLI review) (spiombi2019kctd15inhibitsthe pages 1-2, fiore2023kctd1isa pages 2-3). URL/DOIs: Exp Mol Med 2023 (https://doi.org/10.1038/s12276-023-01087-w); Trends Pharmacol Sci 2015 (https://doi.org/10.1016/j.tips.2015.05.006).

Embedded summary table
| Category | Key finding / definition | Mechanism or partners | Subcellular context | Evidence / source |
|---|---|---|---|---|
| Identity / aliases and locus | KCTD11 (aliases: KCASH1, REN; gene mapped to chromosome 17p13.2) | Human KCTD family member implicated in Hedgehog suppression | Enriched expression in brain / cerebellum | Marcotullio et al., PNAS 2004 (https://doi.org/10.1073/pnas.0400690101), review summary (spiombi2019kctd15inhibitsthe pages 3-4, angrisani2021theemergingrole pages 6-7) |
| Domain architecture & oligomerization | N-terminal BTB/POZ domain (mediates oligomerization and Cullin3 interaction); C-terminal KCTD11/21_C region | BTB drives homo-/hetero-oligomerization (tetramer/pentamer states reported) and Cullin3 adaptor assembly | Forms multimeric adaptor units in cytosol/nuclear interfaces to recruit E3 machinery | Structural/biochemical descriptions and BTB role (navacci2025dissectingtherole pages 31-35, spiombi2019kctd15inhibitsthe pages 3-4) |
| Role as CUL3 adaptor; substrate HDAC1 -> GLI1 effect | Acts as a CUL3 adaptor that promotes HDAC1 ubiquitination and proteasomal degradation, leading to GLI1 hyperacetylation and reduced GLI1 transcriptional activity | Partners: CUL3 (CRL3 complex), RBX1, HDAC1; effect: reduced GLI1 nuclear activity via increased GLI1 acetylation | Impacts GLI1 activity regulated at centrosome/cilium and nucleus (modulates Hh target transcription) | Mechanistic evidence and reviews (angrisani2021theemergingrole pages 6-7, spiombi2019kctd15inhibitsthe pages 3-4) |
| KCASH3 (KCTD6) dependence on KCASH1 | KCASH3 cannot bind HDAC1 directly; requires heterodimerization with KCASH1 (KCTD11) to target HDAC1 | BTB-mediated hetero-oligomerization provides HDAC1 recruitment competence | Functions within CRL3 complexes when partnered with KCASH1 | Functional/biochemical assays showing dependence (spiombi2019kctd15inhibitsthe pages 3-4) |
| Interactions within KCTD family (KCTD6/KCTD21/KCTD15/KCTD1) | KCASH1/KCASH2/KCASH3 form a KCASH subfamily; other KCTDs (KCTD15, KCTD1) can modulate KCASH protein stability | BTB–BTB hetero-oligomerization; modulators (KCTD1/KCTD15) stabilize KCASH proteins, altering ubiquitination dynamics | Alters KCASH half-life and downstream HDAC1 levels in MB cell models | Family interaction and stabilizer findings (fiore2023kctd1isa pages 2-3, spiombi2019kctd15inhibitsthe pages 3-4, fiore2023kctd1isa pages 4-5) |
| 2023 development: KCTD1 effect | KCTD1 (2023, Neoplasia) shown to stabilize KCASH1 and KCASH2 by reducing their ubiquitination; indirectly increases HDAC1 ubiquitination and degradation, lowering GLI1 activity and MB cell proliferation | KCTD1 stabilizes KCASHs (does not directly bind CUL3 or HDAC1) — net effect: enhanced HDAC1 turnover via KCASH-mediated CRL3 activity | Demonstrated in Hh-dependent medulloblastoma cell lines (DAOY, D283) | Fiore et al., Neoplasia 2023 (https://doi.org/10.1016/j.neo.2023.100926) (fiore2023kctd1isa pages 2-3, fiore2023kctd1isa pages 4-5) |
| Disease relevance | Frequent allelic deletions / downregulation of KCTD11 in SHH-medulloblastoma; reduced expression in multiple tumor types; silencing via LOH and promoter methylation reported | Loss of KCTD11 removes negative regulation of Hh pathway -> increased GLI activity and tumorigenesis in cerebellar GNPs | Relevant to granule neuron precursor proliferation/differentiation in cerebellum; constitutional deletions including 17p region linked to developmental phenotypes | Primary identification and expression/silencing studies: Marcotullio PNAS 2004; Mancarelli Mol Cancer 2010; family review Angrisani 2021 (spiombi2019kctd15inhibitsthe pages 3-4, angrisani2021theemergingrole pages 6-7, fiore2023kctd1isa pages 1-2) |
| Localization evidence & GLI regulation context | KCTD11 expression enriched in brain/cerebellum and induced by differentiation cues; GLI1 activity coordinated at centrosome/primary cilium where ubiquitin/DUB machinery acts | Interplay with centrosomal regulators (e.g., USP21 via other KCTDs) influences GLI1 phosphorylation/ubiquitylation/stability and trafficking to nucleus | Centrosome / primary cilium (GLI regulation hub) and nucleus for transcriptional output | Expression/localization and centrosomal regulation references (navacci2025dissectingtherole pages 31-35, spiombi2019kctd15inhibitsthe pages 3-4) |
| Therapeutic implications | Strategies include restoring/reactivating KCASH1/2 (epigenetic demethylation or stabilization), stabilizers of KCASH proteins (e.g., KCTD1-like modulators), and direct targeting of HDAC1 or GLI factors for SHH-MB | Approaches: demethylating agents, modulators of E3-adaptor stability, HDAC inhibitors or GLI antagonists; rationale: reduce nuclear GLI-driven transcription | Aim to decrease oncogenic GLI nuclear activity in SHH-driven tumors | Proposed in reviews and recent studies (Angrisani 2021, Jeong et al. 2023 E3 review, Fiore 2023) (angrisani2021theemergingrole pages 6-7, spiombi2019kctd15inhibitsthe pages 1-2, fiore2023kctd1isa pages 4-5) |

Table: A concise, evidence‑cited table summarizing human KCTD11 (KCASH1/REN): identity, domains, molecular mechanism (CUL3–HDAC1–GLI axis), family interactions including 2023 KCTD1 findings, disease links (17p13.2 deletions in SHH‑MB), localization context, and therapeutic implications with primary citations.

Notes on subcellular localization
- While direct imaging/localization data for human KCASH1 are limited in the sources summarized here, the functional axis places KCASH1 action in proximity to cytosolic/nuclear interfaces affecting GLI1 transcriptional output, and within the broader Hh architecture centered on the primary cilium/centrosome where GLI processing is orchestrated (Nov 2016; Nov 2021 synthesis) (spiombi2019kctd15inhibitsthe pages 3-4, angrisani2021theemergingrole pages 7-9). URL/DOIs: J Cell Sci 2016 (https://doi.org/10.1242/jcs.188516); Cell Commun Signal 2021 (https://doi.org/10.1186/s12964-021-00737-8).

Conclusion
Human KCTD11 (KCASH1/REN) is a BTB/POZ-domain CRL3 adaptor that suppresses Hedgehog signaling by targeting HDAC1 for ubiquitin‑proteasome degradation, thereby increasing GLI1 acetylation and repressing GLI transcription. It is frequently deleted or downregulated in SHH‑medulloblastoma and reduced across multiple cancers. Recent 2023 work identifies KCTD1 as a stabilizer of KCASH1/2, offering a tractable route to augment the KCASH axis. Therapeutically, strategies that restore KCASH1/2, stabilize KCASH adaptors, inhibit HDAC1, or block GLI provide converging approaches to dampen oncogenic Hh signaling (Jul 2004; Jun 2010; Nov 2016; Nov 2019; May 2021; Sep 2023; Oct 2023) (spiombi2019kctd15inhibitsthe pages 3-4, angrisani2021theemergingrole pages 6-7, fiore2023kctd1isa pages 4-5, spiombi2019kctd15inhibitsthe pages 1-2).

References

1. (spiombi2019kctd15inhibitsthe pages 3-4): Eleonora Spiombi, Annapaola Angrisani, Simone Fonte, Giuseppina De Feudis, Francesca Fabretti, Danilo Cucchi, Mariapaola Izzo, Paola Infante, Evelina Miele, Agnese Po, Laura Di Magno, Roberto Magliozzi, Daniele Guardavaccaro, Marella Maroder, Gianluca Canettieri, Giuseppe Giannini, Elisabetta Ferretti, Alberto Gulino, Lucia Di Marcotullio, Marta Moretti, and Enrico De Smaele. Kctd15 inhibits the hedgehog pathway in medulloblastoma cells by increasing protein levels of the oncosuppressor kcash2. Oncogenesis, Nov 2019. URL: https://doi.org/10.1038/s41389-019-0175-6, doi:10.1038/s41389-019-0175-6. This article has 29 citations and is from a domain leading peer-reviewed journal.

2. (angrisani2021theemergingrole pages 6-7): Annapaola Angrisani, Annamaria Di Fiore, Enrico De Smaele, and Marta Moretti. The emerging role of the kctd proteins in cancer. Cell Communication and Signaling : CCS, May 2021. URL: https://doi.org/10.1186/s12964-021-00737-8, doi:10.1186/s12964-021-00737-8. This article has 71 citations.

3. (navacci2025dissectingtherole pages 31-35): S Navacci. Dissecting the role of the cullin3-renkctd11 e3 ubiquitin ligase complex in the control of the hedgehog pathway and medulloblastoma tumorigenesis. Unknown journal, 2025.

4. (fiore2023kctd1isa pages 4-5): A. Di Fiore, S. Bellardinelli, L. Pirone, R. Russo, A. Angrisani, G. Terriaca, M. Bowen, F. Bordin, Z. M. Besharat, G. Canettieri, F. Fabretti, S. Di Gaetano, L. Di Marcotullio, E. Pedone, M. Moretti, and E. De Smaele. Kctd1 is a new modulator of the kcash family of hedgehog suppressors. Neoplasia, 43:100926, Sep 2023. URL: https://doi.org/10.1016/j.neo.2023.100926, doi:10.1016/j.neo.2023.100926. This article has 10 citations and is from a domain leading peer-reviewed journal.

5. (angrisani2021theemergingrole pages 7-9): Annapaola Angrisani, Annamaria Di Fiore, Enrico De Smaele, and Marta Moretti. The emerging role of the kctd proteins in cancer. Cell Communication and Signaling : CCS, May 2021. URL: https://doi.org/10.1186/s12964-021-00737-8, doi:10.1186/s12964-021-00737-8. This article has 71 citations.

6. (fiore2023kctd1isa pages 2-3): A. Di Fiore, S. Bellardinelli, L. Pirone, R. Russo, A. Angrisani, G. Terriaca, M. Bowen, F. Bordin, Z. M. Besharat, G. Canettieri, F. Fabretti, S. Di Gaetano, L. Di Marcotullio, E. Pedone, M. Moretti, and E. De Smaele. Kctd1 is a new modulator of the kcash family of hedgehog suppressors. Neoplasia, 43:100926, Sep 2023. URL: https://doi.org/10.1016/j.neo.2023.100926, doi:10.1016/j.neo.2023.100926. This article has 10 citations and is from a domain leading peer-reviewed journal.

7. (fiore2023kctd1isa pages 5-8): A. Di Fiore, S. Bellardinelli, L. Pirone, R. Russo, A. Angrisani, G. Terriaca, M. Bowen, F. Bordin, Z. M. Besharat, G. Canettieri, F. Fabretti, S. Di Gaetano, L. Di Marcotullio, E. Pedone, M. Moretti, and E. De Smaele. Kctd1 is a new modulator of the kcash family of hedgehog suppressors. Neoplasia, 43:100926, Sep 2023. URL: https://doi.org/10.1016/j.neo.2023.100926, doi:10.1016/j.neo.2023.100926. This article has 10 citations and is from a domain leading peer-reviewed journal.

8. (spiombi2019kctd15inhibitsthe pages 1-2): Eleonora Spiombi, Annapaola Angrisani, Simone Fonte, Giuseppina De Feudis, Francesca Fabretti, Danilo Cucchi, Mariapaola Izzo, Paola Infante, Evelina Miele, Agnese Po, Laura Di Magno, Roberto Magliozzi, Daniele Guardavaccaro, Marella Maroder, Gianluca Canettieri, Giuseppe Giannini, Elisabetta Ferretti, Alberto Gulino, Lucia Di Marcotullio, Marta Moretti, and Enrico De Smaele. Kctd15 inhibits the hedgehog pathway in medulloblastoma cells by increasing protein levels of the oncosuppressor kcash2. Oncogenesis, Nov 2019. URL: https://doi.org/10.1038/s41389-019-0175-6, doi:10.1038/s41389-019-0175-6. This article has 29 citations and is from a domain leading peer-reviewed journal.

9. (fiore2023kctd1isa pages 1-2): A. Di Fiore, S. Bellardinelli, L. Pirone, R. Russo, A. Angrisani, G. Terriaca, M. Bowen, F. Bordin, Z. M. Besharat, G. Canettieri, F. Fabretti, S. Di Gaetano, L. Di Marcotullio, E. Pedone, M. Moretti, and E. De Smaele. Kctd1 is a new modulator of the kcash family of hedgehog suppressors. Neoplasia, 43:100926, Sep 2023. URL: https://doi.org/10.1016/j.neo.2023.100926, doi:10.1016/j.neo.2023.100926. This article has 10 citations and is from a domain leading peer-reviewed journal.

Citations

1. angrisani2021theemergingrole pages 6-7
2. angrisani2021theemergingrole pages 7-9
3. navacci2025dissectingtherole pages 31-35
4. https://doi.org/10.1073/pnas.0400690101
5. https://doi.org/10.1186/s12964-021-00737-8
6. https://doi.org/10.1242/jcs.188516
7. https://doi.org/10.1038/s41389-019-0175-6
8. https://doi.org/10.1016/j.neo.2023.100926
9. https://doi.org/10.1186/1476-4598-9-172
10. https://doi.org/10.1038/s12276-023-01087-w
11. https://doi.org/10.1016/j.tips.2015.05.006
12. https://doi.org/10.1159/000218743
13. https://doi.org/10.3389/fcell.2021.638508
14. https://doi.org/10.1038/s41389-019-0175-6,
15. https://doi.org/10.1186/s12964-021-00737-8,
16. https://doi.org/10.1016/j.neo.2023.100926,

KCTD11 (REN/KCASH1) – Structure, Function, and Biological Significance

Gene and Protein Overview

KCTD11 (Potassium Channel Tetramerization Domain-containing protein 11) is a human gene located on chromosome 17p13.2 that encodes a BTB/POZ domain-containing protein (pmc.ncbi.nlm.nih.gov) (www.proteinatlas.org). Originally identified in neural development studies, KCTD11 (also known by aliases REN and KCASH1) was found to be expressed in differentiating, low-proliferation neural progenitors and absent in rapidly dividing neuroblasts (pmc.ncbi.nlm.nih.gov). It encodes a 246-amino-acid intracellular protein confirmed at the protein level (www.proteinatlas.org). KCTD11 belongs to the broader KCTD family of proteins, which share a conserved BTB (Broad-Complex, Tramtrack, Bric-à-brac)/POZ domain at the N-terminus and are capable of forming oligomeric complexes and acting as substrate adaptors for ubiquitin ligases (biosignaling.biomedcentral.com).

Key structural features: The N-terminal BTB/POZ domain of KCTD11 mediates homo-oligomerization (identical protein binding) and recruitment of CUL3, a Cullin-3 RING ubiquitin ligase scaffold (biosignaling.biomedcentral.com). This allows KCTD11 to function as a substrate-recognition subunit of a CUL3-based E3 ubiquitin ligase complex (sometimes denoted CRL3^REN) (www.nature.com). The C-terminus of KCTD11 (sometimes annotated as the KCTD11/21_C domain) is unique to the KCTD11/21 subfamily and is thought to confer specificity for binding target proteins. KCTD11 lacks known enzymatic motifs; instead, its biological activity derives from serving as an adaptor protein that links target substrates to the ubiquitination machinery (biosignaling.biomedcentral.com). Notably, KCTD11 is one of three closely related BTB-domain adaptors (with KCTD21 and KCTD6) collectively termed the KCASH (KCTD Containing Cullin3 Adaptors Suppressors of Hedgehog) family (biosignaling.biomedcentral.com).

Cellular Localization and Expression Patterns

KCTD11 is an intracellular protein found in both the cytoplasm and nucleus, with predominant localization to the nucleoplasm (www.proteinatlas.org). This nuclear presence aligns with its role in regulating gene expression pathways (see below). The gene is broadly expressed across tissues (low tissue-specificity), with mRNA and protein detectable in many cell types (www.proteinatlas.org). Importantly, brain expression is significant: KCTD11 levels are highest in the cerebellum compared to other brain regions (pmc.ncbi.nlm.nih.gov). During embryonic development, KCTD11 expression is tightly regulated – it is enriched in differentiating neural precursors of the brain’s ventricular zone and largely absent in proliferating neuroblasts (pmc.ncbi.nlm.nih.gov). Consistent with this, experimental studies showed that introducing KCTD11 causes growth arrest and neuronal differentiation in cerebellar progenitor cells (pmc.ncbi.nlm.nih.gov). Thus, under normal physiological conditions KCTD11 helps restrain cell proliferation and promote maturation, particularly in the nervous system (reflected by gene ontology annotations of positive regulation of neuron differentiation and negative regulation of neuroblast proliferation (www.ncbi.nlm.nih.gov)).

In adult tissues, KCTD11 protein is found at moderate levels in most organs. Immunohistochemistry and transcript profiling confirm mixed cytoplasmic/nuclear expression in a variety of cell types, including epithelial cells and glial cells (www.proteinatlas.org). It is not secreted or membrane-bound, in line with its role as an intracellular signaling regulator (www.proteinatlas.org). The widespread but controlled expression of KCTD11 suggests it performs a fundamental cellular function, and disruptions of its expression can have pathological consequences (discussed below).

Mechanism of Action: Cullin-3 Adaptor and Hedgehog Pathway Suppressor

KCTD11’s best-characterized function is as a negative regulator of the Sonic Hedgehog (SHH) signaling pathway, a crucial pathway in embryonic development and cell proliferation. KCTD11 was initially identified as a tumor suppressor frequently lost in medulloblastoma (a pediatric cerebellar tumor), where aberrant Hedgehog signaling drives cancer growth (pmc.ncbi.nlm.nih.gov). Early studies demonstrated that loss of KCTD11 (REN) in medulloblastoma leads to unchecked activity of the Hedgehog effector GLI1, whereas restoring KCTD11 inhibits tumor cell proliferation by antagonizing GLI1-mediated transcription (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In other words, KCTD11 was established as a suppressor of the SHH–Gli pathway, whose inactivation contributes to tumorigenesis in the cerebellum (pmc.ncbi.nlm.nih.gov).

Biochemical function: KCTD11 acts as the substrate-recognition subunit of a Cullin-3/RING E3 ubiquitin ligase complex (CRL3^KCTD11) (www.nature.com). Through its BTB domain, KCTD11 binds to the CUL3 scaffold, positioning specific target proteins for ubiquitination. The primary substrate identified for CRL3^KCTD11 is Histone Deacetylase 1 (HDAC1) (biosignaling.biomedcentral.com). KCTD11 directly interacts with HDAC1 and promotes its polyubiquitination and proteasomal degradation (biosignaling.biomedcentral.com). HDAC1 is an enzyme that normally removes acetyl groups from histones and other proteins; in the context of Hedgehog signaling, HDAC1 is known to deacetylate the GLI1 transcription factor, a modification required for GLI1’s full activity (biosignaling.biomedcentral.com). By targeting HDAC1 for degradation, KCTD11 causes HDAC1 levels to drop, which in turn leads to hyper-acetylation of GLI1 (biosignaling.biomedcentral.com). Acetylated GLI1 is unable to effectively activate Hedgehog target genes, thereby blocking Hedgehog pathway signaling (biosignaling.biomedcentral.com). This mechanism was elucidated in a 2010 study showing that the interplay between the KCTD11–CUL3 ubiquitin ligase and HDAC1 controls GLI1 acetylation status and transcriptional activity (biosignaling.biomedcentral.com) (biosignaling.biomedcentral.com). In cerebellar granule cell progenitors, the net effect of KCTD11 expression is to induce cell-cycle exit, neuronal differentiation, and apoptosis – essentially counteracting the mitogenic effects of Sonic Hedgehog signals (biosignaling.biomedcentral.com).

Additional substrates and interactions: More recent research has expanded the understanding of KCTD11’s role in Hedgehog signaling. In 2023, Infante et al. identified the stemness factor SALL4 as a novel target of the KCTD11–CUL3 E3 complex (www.nature.com). SALL4 is a transcription factor that is abnormally re-expressed in SHH-driven medulloblastomas and correlates with worse patient survival (www.nature.com). Proteomic analysis revealed that KCTD11 (REN) binds SALL4 and induces ubiquitination-dependent degradation of SALL4 (specifically, wild-type SALL4 but not mutants lacking a certain zinc-finger domain) (www.nature.com). This finding is significant because SALL4 binds to GLI1 and recruits HDAC1, forming a complex that deacetylates GLI1 to enhance its activity (www.nature.com). Thus, KCTD11 imposes a double restraint on Hedgehog signaling: it eliminates HDAC1 and eliminates SALL4, both of which are required to keep GLI1 in a deacetylated (active) state (www.nature.com). In the absence of KCTD11, SALL4 and HDAC1 collaborate to hyperactivate GLI1, driving uncontrolled cell proliferation. The discovery of SALL4 as a CRL3^KCTD11 substrate provides a mechanistic explanation for how loss of KCTD11 leads to aggressive SHH-medulloblastomas (www.nature.com). Indeed, approximately 30–50% of SHH-subtype medulloblastomas exhibit loss of KCTD11 function – either through allelic deletion on 17p13.2 or epigenetic silencing – underscoring its role as a major tumor suppressor in this context (www.nature.com) (biosignaling.biomedcentral.com).

It is worth noting that KCTD11 can form heteromeric complexes with its paralogs KCTD6 (KCASH3) and KCTD21 (KCASH2), which are also Cullin3 adaptors that inhibit Hedgehog signaling (biosignaling.biomedcentral.com) (biosignaling.biomedcentral.com). These three proteins share structural features and often act in concert. For example, KCTD6 alone cannot bind HDAC1, but when it heterodimerizes with KCTD11, the complex can still target HDAC1 for degradation (biosignaling.biomedcentral.com). This suggests a cooperative tumor-suppressive network, wherein multiple KCTD adaptors ensure robust repression of the Hedgehog pathway. Together, KCTD11/21/6 (the KCASH family) serve as redundant brakes on SHH signaling during normal cerebellar development and are frequently inactivated in Hh-driven tumors (biosignaling.biomedcentral.com) (biosignaling.biomedcentral.com).

Involvement in Other Signaling Pathways and Cellular Processes

While Hedgehog pathway regulation is the primary known function of KCTD11, emerging evidence shows that KCTD11 influences other oncogenic signaling pathways, highlighting a broader role in maintaining cellular homeostasis:

• Wnt/β-Catenin Pathway: Studies in cancer models have revealed a link between KCTD11 and the Wnt signaling cascade. In non-small cell lung cancer (NSCLC) cells, KCTD11 was found to physically interact with β-catenin (the key transcriptional co-activator in canonical Wnt signaling) (pubmed.ncbi.nlm.nih.gov). Through this interaction, KCTD11 inhibits the nuclear translocation of β-catenin, thereby suppressing Wnt target gene activation (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Experimental overexpression of KCTD11 in NSCLC cell lines led to a significant decrease in Wnt pathway activity (as measured by a TOPflash β-catenin/Tcf reporter assay) and reduced levels of nuclear β-catenin (pubmed.ncbi.nlm.nih.gov). Conversely, siRNA-mediated knockdown of KCTD11 caused an upregulation of Wnt signaling activity (pubmed.ncbi.nlm.nih.gov). By keeping β-catenin out of the nucleus, KCTD11 effectively dampens Wnt-driven transcription of genes involved in proliferation and epithelial-mesenchymal transition (EMT). In line with this, KCTD11 re-expression reversed EMT markers in lung cancer cells: E-cadherin and ZO-1 (epithelial markers) increased, while N-cadherin, vimentin, Snail, and Slug (mesenchymal and EMT-inducing factors) were downregulated (pubmed.ncbi.nlm.nih.gov). Functionally, KCTD11 suppressed the malignant phenotype – reducing NSCLC cell proliferation, invasion, and colony formation, whereas loss of KCTD11 had the opposite effect (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). These findings (Yang et al., J. Cell. Mol. Med. 2021) position KCTD11 as an inhibitor of the Wnt/β-catenin pathway in at least some contexts, achieved by sequestering or destabilizing β-catenin in the cytoplasm. Interestingly, KCTD11’s BTB domain was required for these effects, suggesting the involvement of its ubiquitin-ligase function in modulating Wnt components (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov) (possibly through polyubiquitination of β-catenin or associated regulators, though β-catenin degradation was not explicitly shown in this study).

• Hippo/YAP Pathway: KCTD11 is also implicated in the Hippo signaling pathway, which controls organ size and cell proliferation via the transcriptional co-activator YAP. In lung cancer cells, KCTD11 overexpression was shown to reduce the nuclear accumulation of YAP in parallel with β-catenin (pubmed.ncbi.nlm.nih.gov). YAP and β-catenin often cooperate to drive oncogenic transcription, and KCTD11’s ability to retain both factors in the cytoplasm indicates a coordinated suppression of proliferative signaling (pubmed.ncbi.nlm.nih.gov). In support of this, KCTD11-low NSCLC tumors exhibited higher rates of EMT and metastasis, phenomena typically associated with concurrent Wnt and Hippo pathway activation (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). A separate study in hepatocellular carcinoma (HCC) provides further evidence that KCTD11 activates the Hippo pathway, reinforcing its tumor-suppressive role. Tong et al. (Oncotarget, 2017) reported that KCTD11 is downregulated in HCC, and low expression correlates with shorter patient survival (www.oncotarget.com). Restoring KCTD11 in HCC cells led to increased phosphorylation (activation) of Hippo pathway kinases and functional inactivation of YAP (the downstream effector), as indicated by reduced levels of YAP target genes like CTGF (Connective Tissue Growth Factor) (www.oncotarget.com). Through Hippo pathway activation, KCTD11 induces the cell cycle inhibitor p21 (potentially via stabilization of p53 and activation of MST1 kinase) and triggers cellular senescence or arrest (www.oncotarget.com). In vivo, KCTD11 re-expression slowed HCC tumor growth and metastasis in mouse models (www.oncotarget.com). Molecular analyses showed that KCTD11 decreased pro-metastatic factors (such as MMPs and Claudin-1) and mesenchymal markers, thereby suppressing EMT and invasion (www.oncotarget.com). Notably, Cldn1 and CTGF are direct targets of YAP/TAZ, so their reduction confirms that KCTD11 is effectively turning on Hippo signaling to keep YAP in check (www.oncotarget.com). These data from lung and liver cancers indicate that KCTD11’s tumor-suppressive activity is not limited to Hedgehog pathway inhibition – it also extends to other major growth and differentiation pathways (Wnt and Hippo), likely by promoting the degradation or cytoplasmic retention of key regulators (β-catenin and YAP). In summary, KCTD11 serves as a multi-pathway suppressor of oncogenic signaling, aligning with its frequent loss in diverse tumor types.

Role in Development and Disease

Developmental function: In normal development, KCTD11’s role as a brake on Hedgehog signaling is important for proper patterning and differentiation in the brain. Sonic Hedgehog is required for the proliferation of granule neuron precursors in the developing cerebellum; KCTD11 provides a counterbalance that ensures these cells exit the cell cycle and differentiate at the appropriate time (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Mice with disrupted Hedgehog antagonists often develop cerebellar overgrowth or tumors, underscoring the significance of regulators like KCTD11. While a complete KCTD11 knockout model has not been widely reported in literature, in vitro studies of neural progenitors clearly show that KCTD11 induction causes cessation of proliferation and promotes neuronal differentiation and apoptosis of precursor cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Additionally, KCTD11 (KCASH1) is highly expressed in the postnatal cerebellum, suggesting it contributes to the normal maturation of this brain region (biosignaling.biomedcentral.com). Its induction has also been observed in other differentiation contexts (e.g. peri-ovulatory ovarian cells in rodents), implying a broader role in driving cells towards a differentiated state (biosignaling.biomedcentral.com) (biosignaling.biomedcentral.com).

Tumor suppressor in cancer: KCTD11 is now recognized as a bona fide tumor suppressor gene in humans. Its inactivation is associated with several cancer types, most prominently in SHH-driven medulloblastoma but also in others such as prostate, liver, and lung tumors. In medulloblastoma (MB), the loss of one copy of KCTD11 (17p13 deletion encompassing the KCTD11 locus) is the single most frequent genetic lesion in the SHH subtype, occurring in roughly 30–50% of cases (biosignaling.biomedcentral.com) (www.nature.com). This partial loss (haploinsufficiency) leads to substantially reduced KCTD11 mRNA and protein levels in tumors compared to normal cerebellar tissue (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Even MB tumors without a gross deletion often show dramatically lowered KCTD11 expression due to epigenetic mechanisms (molecular-cancer.biomedcentral.com) (molecular-cancer.biomedcentral.com). Indeed, the promoter region of KCTD11 is a CpG island that is frequently hypermethylated in cancer cell lines and primary tumors, silencing gene transcription (molecular-cancer.biomedcentral.com) (molecular-cancer.biomedcentral.com). Treatment of cancer cells with DNA demethylating agents (5-azacytidine) can reactivate KCTD11 expression, confirming that DNA methylation directly represses KCTD11 in many tumors (molecular-cancer.biomedcentral.com) (molecular-cancer.biomedcentral.com). Additionally, the transcription factor Sp1 has been shown to bind the KCTD11 promoter and protect it from methylation; loss of Sp1 binding or Sp1 inactivation may thus predispose the KCTD11 locus to epigenetic silencing (molecular-cancer.biomedcentral.com) (molecular-cancer.biomedcentral.com). Through a combination of deletion and methylation, KCTD11 is widely downregulated in human cancers (molecular-cancer.biomedcentral.com). For example, studies report reduced KCTD11 expression in prostate carcinoma, colorectal cancer, gastric cancer, breast cancer, lung cancer, bladder cancer, and others (biosignaling.biomedcentral.com). An analysis by Zazzeroni et al. (2014) found significantly lower KCTD11 levels in a broad panel of solid tumors compared to normal tissues (biosignaling.biomedcentral.com). The consistent loss of KCTD11 in cancers aligns with its role in restraining pro-proliferative pathways (Hedgehog, Wnt, YAP). When KCTD11 function is lost, these pathways can become overactive, contributing to uncontrolled growth, survival, and stem-like properties of cancer cells.

Clinically, low KCTD11 expression is associated with more aggressive disease and poorer prognosis in multiple cancers. In medulloblastoma patients, KCTD11 loss (via 17p deletion or low mRNA) correlates with higher-grade tumors and possibly treatment resistance (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In glioblastoma multiforme (GBM), The Human Protein Atlas reports that KCTD11 is a favorable prognostic marker (higher expression linked to better survival) (www.proteinatlas.org). Similarly, immunohistochemistry on NSCLC patient samples (n = 139) showed that low KCTD11 levels significantly correlated with advanced tumor stage, poor differentiation, and lymph node metastasis (pmc.ncbi.nlm.nih.gov). NSCLC patients lacking KCTD11 had worse overall survival on follow-up, indicating its potential use as a prognostic biomarker in lung cancer (pmc.ncbi.nlm.nih.gov). In hepatocellular carcinoma, analysis of 112 cases found that those with low KCTD11 had shorter survival, and multivariate Cox analysis identified KCTD11 expression as an independent prognostic factor (www.oncotarget.com). These data underscore that restoration of KCTD11 tends to suppress tumor progression, whereas its absence exacerbates malignancy.

Current Research Directions and Therapeutic Implications

Given KCTD11’s central role in tumor suppression and pathway regulation, it is drawing interest as a potential diagnostic marker and therapeutic target. Experts have suggested that assessing KCTD11 (KCASH1) expression could aid in cancer prognosis or subtype classification – for instance, SHH-subtype medulloblastomas often coincide with KCASH1/KCTD11 downregulation (biosignaling.biomedcentral.com), and re-expression of KCTD11 might serve as a marker of treatment-induced differentiation. Moreover, reactivating or substituting KCTD11 function in tumors is a concept under exploration. Because KCTD11 itself is not an enzyme, drug strategies focus on upstream and downstream elements: for example, epigenetic drugs (DNA methylation inhibitors or histone acetylation modulators) might be used to demethylate the KCTD11 promoter and restore its expression in tumors where it is silenced (molecular-cancer.biomedcentral.com) (molecular-cancer.biomedcentral.com). In a 2010 study, demethylating colon cancer cells led to a significant increase in KCTD11 mRNA, providing proof-of-principle that epigenetic therapy can upregulate this tumor suppressor (molecular-cancer.biomedcentral.com). Another avenue is targeting the pathways and substrates affected by KCTD11. For instance, the newly identified SALL4–HDAC1–GLI1 axis offers a therapeutic opportunity: even if KCTD11 is lost, inhibiting SALL4 or HDAC1 could mimic KCTD11’s effect and shut down Hedgehog signaling. In fact, the 2023 study showed that pharmacological or genetic inhibition of SALL4 suppressed SHH-medulloblastoma growth in mouse and patient-derived models (www.nature.com). Thus, SALL4 is proposed as a drug target in KCTD11-deficient tumors (www.nature.com). Similarly, in KCTD11-low cancers that show Wnt activation, β-catenin pathway inhibitors might be particularly effective, and in those with YAP overactivity, Hippo pathway activators or YAP inhibitors could be beneficial. Research is ongoing to map the full network of KCTD11 interactions – for example, structural studies (using AlphaFold and cryo-EM) are investigating how KCTD11 assembles into oligomers and binds CUL3 and substrates (biosignaling.biomedcentral.com) (biosignaling.biomedcentral.com). Understanding these interfaces could inform the design of stapled peptides or small molecules that stabilize the KCTD11–CUL3–substrate complex or otherwise enhance its activity.

Expert perspective: Comprehensive reviews of the KCTD protein family highlight KCTD11 as a prototypical tumor suppressor whose loss promotes oncogenesis (biosignaling.biomedcentral.com) (biosignaling.biomedcentral.com). Researchers Di Marcotullio et al. (who first characterized KCTD11) emphasize that KCTD11/KCASH1 is a critical inhibitor of Hh-driven tumorigenesis, and they note that strategies to increase its expression could have therapeutic value in Hedgehog-dependent cancers (biosignaling.biomedcentral.com). Additionally, bioinformatics analyses (COSMIC and TCGA data) have reinforced that KCTD11 is frequently under-expressed in malignancies – for example, one study found KCTD11 mRNA downregulated in ~60% of ovarian carcinoma cases examined (biosignaling.biomedcentral.com). Such findings position KCTD11 as not only a subject of fundamental scientific interest but also a candidate biomarker for cancer diagnosis/prognosis and a node in critical signaling pathways that new drugs might exploit.

In summary, KCTD11 (REN/KCASH1) is a multifaceted protein that serves as a Cullin-3 adaptor to restrain key growth signals in cells. It localizes to the nucleus to mediate ubiquitination of specific substrates (HDAC1, SALL4, etc.), thereby enforcing transcriptional programs that favor differentiation and cell cycle exit. Loss of KCTD11 unleashes developmental pathways like Hedgehog, Wnt, and YAP, contributing to tumor development. Current research (especially from 2017–2024) has broadened our understanding of KCTD11’s interactome and paved the way for translational approaches – for instance, targeting the SALL4–HDAC1–GLI1 circuit in Hedgehog-driven tumors or using KCTD11 expression levels as a predictive clinical marker (www.nature.com) (pmc.ncbi.nlm.nih.gov). As we continue to decode the KCTD11 protein’s functions, it stands out as a crucial regulator of cellular growth and a promising point of intervention in diseases where this regulation fails.

Sources: Comprehensive information was compiled from recent reviews and primary research articles, including a 2021 review on KCTD proteins in cancer (biosignaling.biomedcentral.com) (biosignaling.biomedcentral.com), original studies from 2004–2010 that established KCTD11’s role in Hedgehog signaling (pmc.ncbi.nlm.nih.gov) (biosignaling.biomedcentral.com), and the latest research from 2017–2023 uncovering its interactions with β-catenin, YAP, and SALL4 (pubmed.ncbi.nlm.nih.gov) (www.nature.com). These sources and others are cited in-line to document the current understanding of KCTD11’s function, regulation, and significance in human biology and disease. Each citation includes a URL and reference to the publication or database for verification of the stated findings.

Citations

1. AnnotationURLCitation(end_index=442, start_index=276, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=Allelic%20Deletion%20and%20Decreased%20Expression,amino%20acid%20sequence%20is%2091')
2. AnnotationURLCitation(end_index=618, start_index=443, title='KCTD11 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000213859-KCTD11#:~:text=%7C%20KCTD11%20INFORMATION%20Protein,proteins%20PROTEIN%20EXPRESSION%20AND%20LOCALIZATION')
3. AnnotationURLCitation(end_index=977, start_index=853, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=We%20have%20identified%20REN,Consistently')
4. AnnotationURLCitation(end_index=1195, start_index=1060, title='KCTD11 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000213859-KCTD11#:~:text=Protein,i%7D%20Localized%20to%20the%20Nucleoplasm')
5. AnnotationURLCitation(end_index=1618, start_index=1456, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=of%20group%20B%20%28KCASH1,Cul3%29%20ligase')
6. AnnotationURLCitation(end_index=1978, start_index=1816, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=of%20group%20B%20%28KCASH1,Cul3%29%20ligase')
7. AnnotationURLCitation(end_index=2256, start_index=2121, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=that%20SALL4%20interacts%20with%20REN%2FKCTD11,dependent')
8. AnnotationURLCitation(end_index=2750, start_index=2612, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=as%20REN,22%2C%2013')
9. AnnotationURLCitation(end_index=3136, start_index=2944, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=structural%20and%20functional%20features%20in,and%20thus%20blocking%20its')
10. AnnotationURLCitation(end_index=3485, start_index=3323, title='KCTD11 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000213859-KCTD11#:~:text=PROTEIN%20EXPRESSION%20AND%20LOCALIZATION%20Tissue,Transcription%20%28mainly')
11. AnnotationURLCitation(end_index=3878, start_index=3705, title='KCTD11 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000213859-KCTD11#:~:text=TISSUE%20RNA%20EXPRESSION%20Tissue%20specificity,Loop%20of%20henle%20epithelial%20cells')
12. AnnotationURLCitation(end_index=4164, start_index=4006, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=match%20at%20L192%20Human%20REN,specifically%20affected%20in%20this%20tumor')
13. AnnotationURLCitation(end_index=4497, start_index=4373, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=We%20have%20identified%20REN,Consistently')
14. AnnotationURLCitation(end_index=4782, start_index=4658, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=We%20have%20identified%20REN,Consistently')
15. AnnotationURLCitation(end_index=5225, start_index=5077, title='KCTD11 potassium channel tetramerization domain containing 11 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/147040#:~:text=Enables%20identical%20protein%20binding%20activity,mouse%20%20%2013%20NEW')
16. AnnotationURLCitation(end_index=5651, start_index=5472, title='KCTD11 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000213859-KCTD11#:~:text=Brain%20expression%20cluster%5E%7Bi%7D%20Non,Renal%20collecting%20duct%20intercalated%20cells')
17. AnnotationURLCitation(end_index=5915, start_index=5753, title='KCTD11 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000213859-KCTD11#:~:text=PROTEIN%20EXPRESSION%20AND%20LOCALIZATION%20Tissue,Transcription%20%28mainly')
18. AnnotationURLCitation(end_index=6718, start_index=6552, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=in%20vitro%20and%20suppresses%20xenograft,its%20growth%20inhibitory%20activity%20is')
19. AnnotationURLCitation(end_index=7122, start_index=6956, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=in%20vitro%20and%20suppresses%20xenograft,its%20growth%20inhibitory%20activity%20is')
20. AnnotationURLCitation(end_index=7286, start_index=7123, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=antagonizing%20the%20Gli,potential%20target%20for%20therapeutical%20intervention')
21. AnnotationURLCitation(end_index=7603, start_index=7437, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=in%20vitro%20and%20suppresses%20xenograft,its%20growth%20inhibitory%20activity%20is')
22. AnnotationURLCitation(end_index=7881, start_index=7746, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=that%20SALL4%20interacts%20with%20REN%2FKCTD11,dependent')
23. AnnotationURLCitation(end_index=8227, start_index=8089, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=as%20REN,22%2C%2013')
24. AnnotationURLCitation(end_index=8468, start_index=8330, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=as%20REN,22%2C%2013')
25. AnnotationURLCitation(end_index=8845, start_index=8707, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=as%20REN,22%2C%2013')
26. AnnotationURLCitation(end_index=9114, start_index=8976, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=as%20REN,22%2C%2013')
27. AnnotationURLCitation(end_index=9375, start_index=9237, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=as%20REN,22%2C%2013')
28. AnnotationURLCitation(end_index=9701, start_index=9563, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=as%20REN,22%2C%2013')
29. AnnotationURLCitation(end_index=9883, start_index=9702, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=signalling%3A%20binding%20to%20Cul3%2C%20they,12%20%2C%20%2023')
30. AnnotationURLCitation(end_index=10249, start_index=10107, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=KCASH1,58%20%2C%20%2072')
31. AnnotationURLCitation(end_index=10638, start_index=10503, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=that%20SALL4%20interacts%20with%20REN%2FKCTD11,dependent')
32. AnnotationURLCitation(end_index=10938, start_index=10778, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=show%20that%20the%20pro,potentiate%20GLI1%20deacetylation%20and%20transcriptional')
33. AnnotationURLCitation(end_index=11276, start_index=11141, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=that%20SALL4%20interacts%20with%20REN%2FKCTD11,dependent')
34. AnnotationURLCitation(end_index=11550, start_index=11423, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=lost%20in%20~30,MB%20growth%20both%20in%20murine')
35. AnnotationURLCitation(end_index=11842, start_index=11738, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=lost%20in%20~30,dependent')
36. AnnotationURLCitation(end_index=12248, start_index=12111, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=4%20%28SALL4%29%20is%20re,MB%20growth%20both%20in%20murine')
37. AnnotationURLCitation(end_index=12625, start_index=12488, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=4%20%28SALL4%29%20is%20re,MB%20growth%20both%20in%20murine')
38. AnnotationURLCitation(end_index=12824, start_index=12626, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=Interestingly%2C%20among%20the%20genetic%20alterations,72%2C%2061%20%2C%20%2075')
39. AnnotationURLCitation(end_index=13208, start_index=13016, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=structural%20and%20functional%20features%20in,and%20thus%20blocking%20its')
40. AnnotationURLCitation(end_index=13361, start_index=13209, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=68%20%5D%2C%20neuroblastoma%20,84')
41. AnnotationURLCitation(end_index=13724, start_index=13572, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=68%20%5D%2C%20neuroblastoma%20,84')
42. AnnotationURLCitation(end_index=14233, start_index=14038, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=Group%20B%20is%20composed%20of,the%20ubiquitination%20and%20degradation%20of')
43. AnnotationURLCitation(end_index=14384, start_index=14234, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=KCASH2,12%20%2C%20%2025%2C%2066')
44. AnnotationURLCitation(end_index=15112, start_index=14972, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20%CE%B2,the%20Wnt%20and%20Hippo%20pathways')
45. AnnotationURLCitation(end_index=15387, start_index=15247, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20%CE%B2,the%20Wnt%20and%20Hippo%20pathways')
46. AnnotationURLCitation(end_index=15538, start_index=15388, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20the%20Wnt%20pathway,The%20experiment%20is%20treated')
47. AnnotationURLCitation(end_index=15899, start_index=15749, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20the%20Wnt%20pathway,The%20experiment%20is%20treated')
48. AnnotationURLCitation(end_index=16147, start_index=15997, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20the%20Wnt%20pathway,The%20experiment%20is%20treated')
49. AnnotationURLCitation(end_index=16744, start_index=16563, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20the%20process%20of,Slug%20are%20downregulated%20in%20KCTD11%E2%80%90overexpressing')
50. AnnotationURLCitation(end_index=17106, start_index=16922, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20proliferation%20and%20invasion,cells%20are%20increased%20in%20KCTD11%E2%80%90depleted')
51. AnnotationURLCitation(end_index=17257, start_index=17107, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20the%20Wnt%20pathway,The%20experiment%20is%20treated')
52. AnnotationURLCitation(end_index=17839, start_index=17633, title='KCTD11 inhibits progression of lung cancer by binding to β‐catenin to regulate the activity of the Wnt and Hippo pathways - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8500973/#:~:text=KCTD11%C2%A0has%20been%20reported%20to%20be,assay%2C%20RT%E2%80%90qPCR%2C%20immunofluorescence%20and%20immunoprecipitation')
53. AnnotationURLCitation(end_index=17980, start_index=17840, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20%CE%B2,the%20Wnt%20and%20Hippo%20pathways')
54. AnnotationURLCitation(end_index=18569, start_index=18429, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20%CE%B2,the%20Wnt%20and%20Hippo%20pathways')
55. AnnotationURLCitation(end_index=18903, start_index=18763, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20%CE%B2,the%20Wnt%20and%20Hippo%20pathways')
56. AnnotationURLCitation(end_index=19215, start_index=19075, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20%CE%B2,the%20Wnt%20and%20Hippo%20pathways')
57. AnnotationURLCitation(end_index=19393, start_index=19216, title='KCTD11 inhibits progression of lung cancer by binding to β‐catenin to regulate the activity of the Wnt and Hippo pathways - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8500973/#:~:text=clinicopathological%20factors%20in%20patients%20with,age%2C%20sex%20and%20histological%20type')
58. AnnotationURLCitation(end_index=19853, start_index=19698, title='KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling | Oncotarget', type='url_citation', url='https://www.oncotarget.com/article/17145/#:~:text=problem%20in%20hepatocellular%20carcinoma,We%20found%20KCTD11%20inhibiting%20cell')
59. AnnotationURLCitation(end_index=20269, start_index=20117, title='KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling | Oncotarget', type='url_citation', url='https://www.oncotarget.com/article/17145/#:~:text=repressing%20cycle%20related%20proteins,We%20found%20the%20tumor%20suppression')
60. AnnotationURLCitation(end_index=20611, start_index=20461, title='KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling | Oncotarget', type='url_citation', url='https://www.oncotarget.com/article/17145/#:~:text=match%20at%20L107%20function%20of,suppressor%20and%20owns%20prognostic%20and')
61. AnnotationURLCitation(end_index=20852, start_index=20702, title='KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling | Oncotarget', type='url_citation', url='https://www.oncotarget.com/article/17145/#:~:text=match%20at%20L107%20function%20of,suppressor%20and%20owns%20prognostic%20and')
62. AnnotationURLCitation(end_index=21178, start_index=21026, title='KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling | Oncotarget', type='url_citation', url='https://www.oncotarget.com/article/17145/#:~:text=repressing%20cycle%20related%20proteins,We%20found%20the%20tumor%20suppression')
63. AnnotationURLCitation(end_index=21494, start_index=21342, title='KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling | Oncotarget', type='url_citation', url='https://www.oncotarget.com/article/17145/#:~:text=repressing%20cycle%20related%20proteins,We%20found%20the%20tumor%20suppression')
64. AnnotationURLCitation(end_index=22561, start_index=22390, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=Deregulation%20of%20the%20Sonic%20Hedgehog,Gli%20transcription%20factors%20to%20regulate')
65. AnnotationURLCitation(end_index=22686, start_index=22562, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=We%20have%20identified%20REN,Consistently')
66. AnnotationURLCitation(end_index=23221, start_index=23097, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=We%20have%20identified%20REN,Consistently')
67. AnnotationURLCitation(end_index=23385, start_index=23222, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=antagonizing%20the%20Gli,potential%20target%20for%20therapeutical%20intervention')
68. AnnotationURLCitation(end_index=23680, start_index=23538, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=KCASH1,58%20%2C%20%2072')
69. AnnotationURLCitation(end_index=24067, start_index=23873, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=match%20at%20L307%20KCASH1,theca%20and%20granulosa%20cell%20differentiation')
70. AnnotationURLCitation(end_index=24242, start_index=24068, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=KCASH1,theca%20and%20granulosa%20cell%20differentiation')
71. AnnotationURLCitation(end_index=24925, start_index=24727, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=Interestingly%2C%20among%20the%20genetic%20alterations,72%2C%2061%20%2C%20%2075')
72. AnnotationURLCitation(end_index=25063, start_index=24926, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=4%20%28SALL4%29%20is%20re,MB%20growth%20both%20in%20murine')
73. AnnotationURLCitation(end_index=25320, start_index=25213, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=%28arrow%29,primary%20MB')
74. AnnotationURLCitation(end_index=25482, start_index=25321, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=cell%20lines%20for%20REN%20ploidy,blood%20cells%2C%20in%20healthy%20volunteers')
75. AnnotationURLCitation(end_index=25817, start_index=25607, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=transcription%20factor%20and%20DNA%20methylation,be%20deregulated%20in%20tumor%20cells')
76. AnnotationURLCitation(end_index=26019, start_index=25818, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=whether%20methylation%20might%20regulate%20KCTD11,It%20is%20worth%20to%20note')
77. AnnotationURLCitation(end_index=26353, start_index=26184, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=We%20found%20a%20putative%20CpG,To%20evaluate')
78. AnnotationURLCitation(end_index=26528, start_index=26354, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=KCTD11%20is%20silenced%20by%20methylation,15%20and')
79. AnnotationURLCitation(end_index=26914, start_index=26713, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=whether%20methylation%20might%20regulate%20KCTD11,It%20is%20worth%20to%20note')
80. AnnotationURLCitation(end_index=27098, start_index=26915, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=clearly%20demonstrate%20a%20direct%20role,the%20region%20in')
81. AnnotationURLCitation(end_index=27508, start_index=27324, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=methylation,chromosomal%20region%2017p13%2C%20where%20KCTD11')
82. AnnotationURLCitation(end_index=27720, start_index=27509, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=methylation%20contributed%2C%20at%20least%20in,cancers%20of%20specific%20tissue%20types')
83. AnnotationURLCitation(end_index=28035, start_index=27825, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=transcription%20factor%20and%20DNA%20methylation,be%20deregulated%20in%20tumor%20cells')
84. AnnotationURLCitation(end_index=28393, start_index=28208, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=A%20significant%20reduction%20of%20KCASH1,mesenchymal%20transition')
85. AnnotationURLCitation(end_index=28713, start_index=28536, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=The%20tumor%20suppressor%20gene%20KCTD11REN,2010%3B9%3A172')
86. AnnotationURLCitation(end_index=29425, start_index=29268, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=Here%2C%20we%20describe%20the%20human,sporadic%20human%20MB%2C%20and%20its')
87. AnnotationURLCitation(end_index=29589, start_index=29426, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=antagonizing%20the%20Gli,potential%20target%20for%20therapeutical%20intervention')
88. AnnotationURLCitation(end_index=29910, start_index=29752, title='KCTD11 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000213859-KCTD11#:~:text=Prognostic%20summary%20KCTD11%20is%20a,i%7D%20Low%20cancer%20specificity')
89. AnnotationURLCitation(end_index=30290, start_index=30113, title='KCTD11 inhibits progression of lung cancer by binding to β‐catenin to regulate the activity of the Wnt and Hippo pathways - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8500973/#:~:text=clinicopathological%20factors%20in%20patients%20with,age%2C%20sex%20and%20histological%20type')
90. AnnotationURLCitation(end_index=30610, start_index=30433, title='KCTD11 inhibits progression of lung cancer by binding to β‐catenin to regulate the activity of the Wnt and Hippo pathways - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8500973/#:~:text=clinicopathological%20factors%20in%20patients%20with,age%2C%20sex%20and%20histological%20type')
91. AnnotationURLCitation(end_index=30972, start_index=30817, title='KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling | Oncotarget', type='url_citation', url='https://www.oncotarget.com/article/17145/#:~:text=problem%20in%20hepatocellular%20carcinoma,We%20found%20KCTD11%20inhibiting%20cell')
92. AnnotationURLCitation(end_index=31693, start_index=31543, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=KCASH2,12%20%2C%20%2025%2C%2066')
93. AnnotationURLCitation(end_index=32390, start_index=32189, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=whether%20methylation%20might%20regulate%20KCTD11,It%20is%20worth%20to%20note')
94. AnnotationURLCitation(end_index=32575, start_index=32391, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=methylation,chromosomal%20region%2017p13%2C%20where%20KCTD11')
95. AnnotationURLCitation(end_index=32964, start_index=32763, title='The tumor suppressor gene KCTD11 REN is regulated by Sp1 and methylation and its expression is reduced in tumors | Molecular Cancer | Full Text', type='url_citation', url='https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-172#:~:text=whether%20methylation%20might%20regulate%20KCTD11,It%20is%20worth%20to%20note')
96. AnnotationURLCitation(end_index=33528, start_index=33414, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=lost%20in%20~30,dependent%20cancers')
97. AnnotationURLCitation(end_index=33738, start_index=33602, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=lacking%20zinc%20finger%20cluster%201,dependent%20cancers')
98. AnnotationURLCitation(end_index=34318, start_index=34184, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=medulloblastoma')
99. AnnotationURLCitation(end_index=34474, start_index=34319, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=13,2010%3B12%282%29%3A132%E2%80%9342')
100. AnnotationURLCitation(end_index=35009, start_index=34814, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=Group%20B%20is%20composed%20of,the%20ubiquitination%20and%20degradation%20of')
101. AnnotationURLCitation(end_index=35152, start_index=35010, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=KCASH1,58%20%2C%20%2072')
102. AnnotationURLCitation(end_index=35620, start_index=35424, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=Although%20it%20is%20likely%20that,treating%20different%20type%20of%20cancers')
103. AnnotationURLCitation(end_index=36063, start_index=35864, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=Finally%2C%20analysis%20of%20the%20COSMIC,the%20authors%20have%20observed%20that')
104. AnnotationURLCitation(end_index=37146, start_index=37032, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=lost%20in%20~30,dependent%20cancers')
105. AnnotationURLCitation(end_index=37324, start_index=37147, title='KCTD11 inhibits progression of lung cancer by binding to β‐catenin to regulate the activity of the Wnt and Hippo pathways - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8500973/#:~:text=clinicopathological%20factors%20in%20patients%20with,age%2C%20sex%20and%20histological%20type')
106. AnnotationURLCitation(end_index=37872, start_index=37677, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=Group%20B%20is%20composed%20of,the%20ubiquitination%20and%20degradation%20of')
107. AnnotationURLCitation(end_index=38011, start_index=37873, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=as%20REN,22%2C%2013')
108. AnnotationURLCitation(end_index=38264, start_index=38098, title='RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC490020/#:~:text=in%20vitro%20and%20suppresses%20xenograft,its%20growth%20inhibitory%20activity%20is')
109. AnnotationURLCitation(end_index=38403, start_index=38265, title='The emerging role of the KCTD proteins in cancer | Cell Communication and Signaling | Full Text', type='url_citation', url='https://biosignaling.biomedcentral.com/articles/10.1186/s12964-021-00737-8#:~:text=as%20REN,22%2C%2013')
110. AnnotationURLCitation(end_index=38643, start_index=38503, title='KCTD11 inhibits progression of lung cancer by binding to β-catenin to regulate the activity of the Wnt and Hippo pathways - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34453479/#:~:text=KCTD11%20inhibits%20%CE%B2,the%20Wnt%20and%20Hippo%20pathways')
111. AnnotationURLCitation(end_index=38779, start_index=38644, title='SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma | Cell Death & Differentiation', type='url_citation', url='https://www.nature.com/articles/s41418-023-01246-6#:~:text=that%20SALL4%20interacts%20with%20REN%2FKCTD11,dependent')